Northern Minerals raises $10 million at premium to par

|

Published 21-MAR-2017 15:32 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Australian heavy rare earths developer, Northern Minerals (ASX:NTU) has raised $10 million in a placement that was negotiated at a 4% premium to its last closing price. The funds will be used in the development of the Browns Range project which spans the Western Australian and Northern Territory border.

At a stage when most mining companies are accepting a considerable discount for capital raisings, NTU has achieved an underwritten placement at 13.5 cents per share compared with its last closing price of 13 cents per share.

The placement which management said received strong interest was underwritten by Hong Kong-based AMC Wanhai Securities.

NTU has already received applications and cleared funds for the first $2 million of the placement. Importantly, the prospective earnings per share dilution based on the number of shares issued is less than 10%.

The timing of the placement is important given NTU is approaching the Final Investment Decision regarding its Browns Range Pilot Plant Project.

This is an early stage play and investors should seek professional financial advice for further information if considering this stock for their portfolio.

Managing Director, George Bauk, noted the premium placement was not just financially beneficial, but an endorsement of the investment appeal of the Browns Range heavy rare earth project.

NTU’s key focus is on the production of dysprosium, an essential ingredient in the production of magnets used in clean energy and high technology solutions. With these applications being related to fast-growing industries, demand for the product is increasing.

NTU has predominately traded in a tight range between 11 cents and 13 cents in 2017 after retracing from a 12 month high of 17.5 cents. While this trend could continue, one would expect an affirmative decision to build the pilot plant could be a share price catalyst.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X